NewAmsterdam Pharma Company NAMS Gain/(loss) on dispositions, net

Gain/(loss) on dispositions, net at other companies

Comfort Systems USAFIX

$302K-45.7%

Enterprise Products PartnersEPD

-$1M-150%

Healthcare Realty TrustHR

$10.78M+271%

Datadog, Inc.DDOG

-$1.13M-882%

Digital RealtyDLR

$42.87M-70.4%

NetSTREITNTST

$119K-94.3%

Other financials

Income statement

See full

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Balance sheet

See full

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Cash flow

See full

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Valuation

See full

Market cap$3.67B+63.7%

Profitability

See full

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Returns & leverage

See full

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Where this comes from

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about NewAmsterdam Pharma Company's gain/(loss) on dispositions, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NewAmsterdam Pharma Company's gain/(loss) on dispositions, net?: NewAmsterdam Pharma Company (NAMS) reported gain/(loss) on dispositions, net of -$12K in Q1 2026.